Shatavari Shows Measurable Changes in PCOS Stress and Follicle Count in First Double-Blind RCT
Polycystic ovary syndrome (a hormonal condition in which small, immature follicles accumulate on the ovaries, disrupting normal reproductive function, commonly abbreviated as PCOS) affects up to 13% of women of reproductive age worldwide according to the WHO. Despite its prevalence, evidence-based options from the natural supplement space have remained thin. Now, for the first time, shatavari (Asparagus racemosus root extract), a herb long central to Ayurvedic medicine and colloquially called “the woman’s herb,” has completed a rigorous double-blind, placebo-controlled randomized controlled trial. The results, published in Frontiers in Endocrinology in 2026, mark a meaningful step in clinical validation for a supplement category that has relied heavily on tradition rather than trial data.
How the Study Was Designed
Researchers enrolled 70 women between the ages of 20 and 40 diagnosed with PCOS. Participants were randomly assigned to either shatavari extract or a matched placebo and followed for 12 weeks. Neither participants nor assessors knew which group was which. Sixty-six women completed the full study period.
Measurements taken at baseline and endpoint included the Perceived Stress Scale (PSS, a validated questionnaire that quantifies how often individuals feel overwhelmed or out of control in their daily lives), ultrasound assessments of follicle count, endometrial thickness, and ovarian volume, along with BMI, key reproductive hormone levels (LH, FSH, estrogen, progesterone), and standard laboratory panels.
What Changed, and What Did Not
After 12 weeks, three outcomes reached statistical significance in the shatavari group.
Perceived stress scores dropped by an average of 6.64 points (PSS change: -6.64 ± 3.99, p < 0.0001). Women with PCOS carry a disproportionately high psychological burden relative to their peers. A reduction of more than 6 points on this scale reflects a tangible shift in day-to-day stress experience, not just a marginal fluctuation.
Follicle count decreased significantly (p < 0.0001). One of the defining features of PCOS on ultrasound is an excess of small, immature follicles that fail to develop normally. A statistically significant reduction in this count suggests a structural change in ovarian activity.
Endometrial thickness increased (p = 0.028). The lining of the uterus is often thinner in women with PCOS, which can affect fertility. An increase in thickness points toward a positive shift in reproductive readiness indicators.
Four outcomes did not reach significance: ovarian volume (p = 0.254), BMI, hormone levels including LH and FSH, and laboratory markers such as blood glucose and insulin. This distinction matters. Shatavari appears to selectively influence certain aspects of PCOS rather than broadly resetting the underlying endocrine disruption. The absence of hormonal changes, in particular, leaves the mechanism of action unclear.
Safety Profile
Mild to moderate adverse events were reported in 11.4% of the shatavari group and 8.5% of the placebo group. The difference is small and no serious adverse events were documented. Across 12 weeks of use, the safety picture was reassuring.
Where the Market and the Research Intersect
The global women’s health supplement market is currently valued at approximately $77 billion and is projected to grow at a CAGR of 5.25% through 2030. Within that broader category, the fertility and reproductive health supplement segment is expanding even faster, at a CAGR of 8.1% from 2024 to 2030 (Grand View Research). Shatavari has been one of the fastest-moving Ayurvedic herbs into mainstream retail since 2025. This trial is the first to bring a double-blind, controlled evidence base to that commercial momentum.
What the Limitations Mean
The researchers are candid about the boundaries of these findings. A sample of 66 completers is modest for a condition as heterogeneous as PCOS. Twelve weeks does not capture long-term hormonal trajectories or fertility outcomes. And without a corresponding shift in LH, FSH, or ovarian volume, the biological pathway linking shatavari to follicle changes remains speculative.
PCOS is a multifactorial condition. It does not respond to any single intervention across all its features. This study positions shatavari as a potential contributor to stress reduction and follicle-related outcomes, two areas where PCOS management options are genuinely limited. That is a more precise claim than the herb has historically been given credit for, and a more honest one than the category often makes.
Is there clinical evidence that shatavari works for PCOS?
A double-blind, placebo-controlled RCT published in Frontiers in Endocrinology 2026 found that 12 weeks of shatavari extract significantly reduced perceived stress scores (p < 0.0001) and follicle count (p < 0.0001) in women with PCOS. The sample size was 70 participants, and the study duration was 12 weeks, so long-term effects still need further investigation.
Are there safety concerns with shatavari supplementation?
No serious adverse events were reported in this study. Mild to moderate side effects occurred in 11.4% of the shatavari group versus 8.5% in the placebo group. The overall safety profile was favorable, but women who are pregnant or taking other medications should consult a healthcare provider before use.
What should women with PCOS look for when choosing a shatavari supplement?
The study used a standardized Asparagus racemosus extract. When selecting a product, check for a standardized extract ratio and clearly stated ingredient amounts. Since no significant effects were seen on hormone levels or BMI, shatavari is best approached as a complementary tool alongside lifestyle management, not a standalone PCOS treatment.